T1	Participants 503 638	Adult patients with measurable, locally advanced, and/or metastatic RCC were randomly assigned 2:1 to receive oral pazopanib or placebo
T2	Participants 902 914	435 patients
T3	Participants 925 994	233 were treatment naive (54%) and 202 were cytokine pretreated (46%)
